The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer.

Pfizer had appealed against draft guidance from NICE that rejected Vyndaqel for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) on cost grounds. The pharma unsuccessfully appealed against ...

The management expressed confidence in the ongoing conversion of patients to Attruby and noted the early adoption driven by first-line (1L) use in ATTR-CM, a heart condition. They anticipate that ...

The management expressed confidence in the ongoing conversion of patients to Attruby and noted the early adoption driven by first-line (1L) use in ATTR-CM, a heart condition. They anticipate that ...

Treatment with acoramidis reduces the composite of all-cause mortality or first hospitalization due to a cardiovascular event in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) ...

The ability to accurately predict survival/life expectancy in ATTR-CM can better inform clinical decision-making. In incurable illnesses of which prognosis is poor, the ability to provide patients ...

Meeting to be held in Boston on April 8 and in New York on April 9 hosted by Piper Sandler. Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...